Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer (mNSCLC) Tyrosine Kinase Inhibitors (TKI) Therapy
Pfizer
This competitive program seeks to champion patient and caregiver education on long-term safety, prolonged duration of treatment and therapy management and support of ALK+ patients. This grant program is focussed on the management of patients on ALK TKIs in mNSCLC by developing tools to support patients and caregivers, education from academic centers to community centers, and for optimizing care by multidisciplinary teams.
Individual projects requesting up to $100,000 CAD will be considered. Maximum project length is 1.5 years.
Deadlines
| UM Internal Deadline (to ADR) | Sponsor Deadline | |
|---|---|---|
Application | 01-Apr-2026 | 22-Apr-2026 11:59 pm EST |
Important
The information in this directory is provided as a service to the University Community and anyone with legitimate business with the University. Use of this directory to prepare mass mailings is prohibited.